<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04801849</url>
  </required_header>
  <id_info>
    <org_study_id>10 VEDS</org_study_id>
    <secondary_id>U24DK061730</secondary_id>
    <secondary_id>U01DK061732</secondary_id>
    <secondary_id>U01DK061713</secondary_id>
    <secondary_id>U01DK061737</secondary_id>
    <secondary_id>U01DK061728</secondary_id>
    <secondary_id>U01DK061718</secondary_id>
    <secondary_id>U01DK061734</secondary_id>
    <secondary_id>U01DK061738</secondary_id>
    <secondary_id>U01DK061731</secondary_id>
    <nct_id>NCT04801849</nct_id>
  </id_info>
  <brief_title>Vitamin E Dosing Study</brief_title>
  <acronym>VEDS</acronym>
  <official_title>Vitamin E Dosing Study (VEDS): A Dose Finding Study of Vitamin E for the Treatment of Adult NAFLD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double masked, placebo-controlled, parallel treatment&#xD;
      groups dosing trial of Vitamin E in adult nonalcoholic fatty liver disease (NAFLD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adults age 18 years or older will be enrolled for 48 weeks and treated with 200 international&#xD;
      units (IU), 400 IU, or 800 IU of Vitamin E or matching placebo for 24 weeks. The primary&#xD;
      objective of the study is to determine the minimum effective dose of Vitamin E&#xD;
      (d-alpha-tocopherol) based upon relative change in alanine aminotransferase (ALT) from&#xD;
      baseline to 24 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>multicenter, randomized, double masked, placebo-controlled, parallel treatment groups</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative change in alanine aminotransferase (ALT) from baseline to 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>ALT value in units/liter (U/L)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving normalization of alanine aminotransferase (ALT) at 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>Normalization of ALT (U/L) is defined as a decrease in ALT to less than or equal to the ULN at the 24 week visit among participants who had an ALT value greater than ULN at baseline. Values for upper limits of normal (ULN) are defined at each clinical center per institutional guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in serum alanine aminotransferase (ALT) from baseline</measure>
    <time_frame>24 weeks</time_frame>
    <description>ALT value in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in serum aspartate aminotransferase (AST) from baseline</measure>
    <time_frame>24 weeks</time_frame>
    <description>AST value in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in hepatic steatosis (fat in the liver) score determined by Fibroscan® Controlled Attenuation Parameter (CAP) software function</measure>
    <time_frame>24 weeks</time_frame>
    <description>CAP (Control Attenuation Parameter) is expressed in decibels per meter (dB/m). This value is the median of all valid measurements performed during the examination. It ranges from 100 to 400 dB/m. Higher dB/m indicates worse liver fat.&#xD;
238 to 260 dB/m: 11% to 33% of liver with fatty change; 260 to 290 dB/m: 34% to 66% of liver with fatty change; 290 to 400 dB/m: at least 67% of liver with fatty change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in liver stiffness from baseline assessed by Fibroscan®</measure>
    <time_frame>24 weeks</time_frame>
    <description>Fibroscan® measures stiffness in kiloPascal's (kPa) and ranges from 2 to 75. Normal range of FibroScan is between 2 to 7 kPa, and the average normal result is 5.3kPa. Higher kPa means more stiffness (scarring).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Nonalcoholic Fatty Liver Disease</condition>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Vitamin E, 200 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 IU of d-alpha tocopherol (vitamin E) taken once daily with breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin E, 400 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 IU of d-alpha tocopherol (vitamin E) taken once daily with breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin E, 800 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>800 IU of d-alpha tocopherol (vitamin E) taken once daily with breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo taken once daily with breakfast</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>d-alpha-tocopherol</intervention_name>
    <description>Participants will be assigned to take 200 IU, 400 IU, or 800 IU of vitamin E in matching capsules daily for 24 weeks</description>
    <arm_group_label>Vitamin E, 200 IU</arm_group_label>
    <arm_group_label>Vitamin E, 400 IU</arm_group_label>
    <arm_group_label>Vitamin E, 800 IU</arm_group_label>
    <other_name>vitamin E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will take a placebo vitamin E capsule daily for 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older as of the initial screening interview and provision of&#xD;
             consent&#xD;
&#xD;
          -  FibroScan CAP&gt;280 dB/m within 60 days prior to randomization.&#xD;
&#xD;
          -  ALT ≥ 60 U/L within 30 days of randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent or prior use (within 90 days) of vitamin E supplements in excess of 40&#xD;
             IU/day&#xD;
&#xD;
          -  Current or history of significant alcohol consumption for a period of more than 3&#xD;
             consecutive months within 1 year prior to screening (significant alcohol consumption&#xD;
             is defined as more than 20 g/day (~1.5 drinks/day) (&gt; 10.5 drinks per week) in females&#xD;
             and more than 30 g/day (~2 drinks/day) (&gt;14 drinks per week) in males, respectively.&#xD;
             One &quot;standard&quot; drink (or one alcoholic drink equivalent) contains roughly 14 grams of&#xD;
             pure alcohol, which is found in: 12 ounces of regular beer, 5 ounces of wine, or 1.5&#xD;
             ounces of distilled spirits).&#xD;
&#xD;
          -  Inability to reliably quantify alcohol consumption based upon local study physician&#xD;
             judgment&#xD;
&#xD;
          -  Continued use of drugs historically associated with NAFLD (amiodarone, methotrexate,&#xD;
             systemic glucocorticoids, tetracyclines, tamoxifen, estrogens at doses greater than&#xD;
             those used for hormone replacement, anabolic steroids, valproic acid, and other known&#xD;
             hepatotoxins) for more than 2 weeks in the 6 months prior to randomization&#xD;
&#xD;
          -  Current use of anticoagulation therapy (not including antiplatelet agents such as&#xD;
             aspirin or clopidogrel)&#xD;
&#xD;
          -  Platelet count below 150,000 /mm3 within 90 days of randomization&#xD;
&#xD;
          -  History of condition(s) that cause increased risk of bleeding, including hemophilia A,&#xD;
             hemophilia B, von Willebrand disease, or other clotting factor deficiencies.&#xD;
&#xD;
          -  Prior or planned (during the study period) bariatric surgery (eg, gastroplasty,&#xD;
             roux-en-Y gastric bypass)&#xD;
&#xD;
          -  Uncontrolled diabetes defined as HbA1c 9.5% or higher within 60 days prior to&#xD;
             randomization&#xD;
&#xD;
          -  Clinical evidence of hepatic decompensation as defined by the presence of any of the&#xD;
             following abnormalities:&#xD;
&#xD;
               -  Serum albumin less than 3.2 g/dL&#xD;
&#xD;
               -  International Normalized Ratio (INR) greater than 1.3&#xD;
&#xD;
               -  Direct bilirubin greater than 1.0 mg/dL&#xD;
&#xD;
               -  History of esophageal varices, ascites or hepatic encephalopathy&#xD;
&#xD;
          -  Evidence of other forms of chronic liver disease:&#xD;
&#xD;
               -  Hepatitis B as defined by presence of hepatitis B surface antigen (HBsAg)&#xD;
&#xD;
               -  Hepatitis C as defined by presence of hepatitis C virus (HCV) RNA&#xD;
&#xD;
               -  Evidence of ongoing autoimmune liver disease as defined by compatible liver&#xD;
                  histology&#xD;
&#xD;
               -  Primary biliary cirrhosis as defined by the presence of at least 2 of these&#xD;
                  criteria (i) Biochemical evidence of cholestasis based mainly on alkaline&#xD;
                  phosphatase elevation (ii) Presence of anti-mitochondrial antibody (AMA) (iii)&#xD;
                  Histologic evidence of nonsuppurative destructive cholangitis and destruction of&#xD;
                  interlobular bile ducts[1]&#xD;
&#xD;
               -  Primary sclerosing cholangitis&#xD;
&#xD;
               -  Known history of Wilson disease, alpha-1-antitrypsin liver disease, or&#xD;
                  hemochromatosis. Any other type of liver disease that is currently active other&#xD;
                  than NASH such as drug-induced liver disease, liver cancer, or bile duct&#xD;
                  obstruction.&#xD;
&#xD;
          -  Serum alanine aminotransferase (ALT) greater than 400 U/L within 90 days of&#xD;
             randomization&#xD;
&#xD;
          -  Moderate or severe renal impairment (serum creatinine ≥ 2.0 mg/dL or eGFR &lt; 60&#xD;
             mg/mL/1.73m2)&#xD;
&#xD;
          -  History of biliary diversion or evidence of current biliary obstruction&#xD;
&#xD;
          -  Known positivity for Human Immunodeficiency Virus (HIV) infection&#xD;
&#xD;
          -  Active, serious medical disease with likely life expectancy less than 5 years&#xD;
&#xD;
          -  Active substance abuse including inhaled or injection drugs in the year prior to&#xD;
             screening&#xD;
&#xD;
          -  Pregnancy, planned pregnancy, potential for pregnancy and unwillingness to use ≥ 1&#xD;
             effective form(s) of birth control during the trial, breast feeding&#xD;
&#xD;
          -  Current use of medications that may impact the absorption of fat-soluble vitamins&#xD;
             (i.e. orlistat or cholestyramine)&#xD;
&#xD;
          -  Pre-existing history of fat malabsorption&#xD;
&#xD;
          -  Males at high risk of prostate cancer, including:&#xD;
&#xD;
               -  PSA &gt;ULN at baseline&#xD;
&#xD;
               -  History of prostate cancer&#xD;
&#xD;
               -  Age 45 or older with a first-degree relative (father or brother) diagnosed with&#xD;
                  prostate cancer at an early age (younger than age 65).&#xD;
&#xD;
               -  Age 40 or older with more than one first-degree relative who had prostate cancer&#xD;
                  at an early age (younger than age 65)&#xD;
&#xD;
          -  Participation in an IND trial in the 30 days before randomization&#xD;
&#xD;
          -  Any other condition which, in the opinion of the investigator, would impede compliance&#xD;
             or hinder completion of the study, including inability to swallow treatment capsules&#xD;
&#xD;
          -  Failure or inability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arun Sanyal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily Sharkey, MS, MBA</last_name>
    <phone>410-955-8183</phone>
    <email>esharke5@jhu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Miriel, BS</last_name>
    <email>lmiriel1@jhu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Egbert Madamba</last_name>
      <phone>858-246-1394</phone>
      <email>emadamba@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Richards</last_name>
      <email>lrichards@ucsd.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rohit Loomba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Christy Rico</last_name>
      <phone>323-442-1100</phone>
      <email>christy.rico@med.usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Daisy Olvera</last_name>
      <phone>(323) 442-0535</phone>
      <email>daisy.olvera@med.usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Norah Terrault, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rae Davis</last_name>
      <phone>415-514-3274</phone>
      <email>rayshawnda.davis@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Remi Awe</last_name>
      <phone>(415) 502-2906</phone>
      <email>remilekun.awe@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Norah Terrault, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bilal Hameed, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University- Adults</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Theresa Cattoor, RN</last_name>
      <phone>314-977-9355</phone>
      <email>theresa.cattooor@health.slu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Shirley Campbell</last_name>
      <phone>(314) 977-9336</phone>
      <email>shirley.campbell@health.slu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Brent Tetri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Mariko Kopping</last_name>
      <phone>919-684-4798</phone>
      <email>mariko.kopping@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Buie</last_name>
      <phone>(919) 684-4138</phone>
      <email>stephanie.buie@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Anna Mae Diehl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manal Abdelmalek, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Alina Tuladhar</last_name>
      <phone>216-445-0688</phone>
      <email>tuladha@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Annette Bellar</last_name>
      <phone>(216) 636-5247</phone>
      <email>bellara@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Srinivasan Dasarathy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sherry Boyett</last_name>
      <phone>804-828-5434</phone>
      <email>slboyett@vcu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jolene Schlosser</last_name>
      <phone>(804) 828-9195</phone>
      <email>jschlosser@vcu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Arun J Sanyal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liver Institute Northwest</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Tommy Clark</last_name>
      <phone>206-536-3030</phone>
      <email>tclark@liverinstitutenw.org</email>
    </contact>
    <contact_backup>
      <last_name>Heather Harris</last_name>
      <phone>(206) 536-3030</phone>
      <email>hharris@liverinstitutenw.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kris Kowdley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://jhuccs1.us/nash/open/centers/centers.htm</url>
    <description>Nonalcoholic Steatohepatitis Clinical Research Network Centers</description>
  </link>
  <link>
    <url>http://www2.niddk.nih.gov/</url>
    <description>The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 12, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin E</keyword>
  <keyword>Nonalcoholic Fatty Liver Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>This study will comply with the NIH Data Sharing Policy and Results information from this trial will be submitted to ClinicalTrials.gov and a public use database deposited with the NIDDK Central Repository.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data from this study may be requested from the NIDDK Central Repository (https://www.niddkrepository.org/search/study/) two years after the completion of the primary outcome.</ipd_time_frame>
    <ipd_access_criteria>Apply through the NIDDK Central Repository:</ipd_access_criteria>
    <ipd_url>http://repository.niddk.nih.gov/home/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

